Approval

Kanghong Pharmaceutical gets Chinese marketing approval for ibrutinib capsules

China's drug regulator issued Chengdu Kanghong Pharmaceutical Group a registration certificate for ibrutinib capsules, a BTK inhibitor. The listed uses include mantle cell lymphoma, CLL/SLL and Waldenström's macroglobulinemia. The company says the product adds to its cancer portfolio.

Written by Gosset from public sources. Source types: News article. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call